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ess: lars.thorsson@astraSummary Inhaled corticosteroids (ICSs) have become the mainstay of chronic
controller therapy to treat airways inflammation in asthma and to reduce
exacerbations in chronic obstructive pulmonary disease. An array of ICSs are now
available that are aerosolized by a range of delivery systems. Such devices include
pressurized (or propellant) metered-dose inhalers (pMDIs), pMDIs plus valved holding
chambers or spacers, breath-actuated inhalers, and nebulizers. More recently, dry-
powder inhalers (DPIs) were developed to help overcome problems of hand–breath
coordination associated with pMDIs.
The clinical benefit of ICSs therapy is determined by a complex interplay between
the nature and severity of the disease, the type of drug and its formulation, and
characteristics of the delivery device together with the patient’s ability to use the
device correctly.
The ICSs budesonide is available by pMDI, DPI, and nebulizer—allowing the
physician to select the best device for each individual patient. Indeed, the
availability of budesonide in three different delivery systems allows versatility for
the prescribing physician and provides continuity of drug therapy for younger
patients who may remain on the same ICSs as they mature.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
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Asthma and chronic obstructive pulmonary disease
(COPD) are common respiratory conditions that have
a major impact on society in terms of morbidity,
mortality, and costs. They are characterized byed.
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variable airflow limitation. The worldwide preva-
lence of both diseases is increasing, together with
the concomitant implications for the health of the
population and the cost to society.1,2
Anti-inflammatory and bronchodilator medications
for asthma and COPD are delivered by inhalation to
the affected sites—the airways and lungs. Topical
application of these drugs to the lung maximizes
efficacy and minimizes potential side effects. Inhaled
corticosteroids (ICSs) are more effective than cro-
mones or leukotriene modifiers in the control of
asthma and are now regarded as the preferred
therapy for patients with mild, moderate, or severe
persistent asthma.3,4 In addition, a variety of delivery
systems are used to target ICSs to the airways,
including pressurized (or propellant) metered-dose
inhalers (pMDIs), pMDIs plus valved holding chambers
or spacers, breath-actuated MDIs, dry-powder inha-
lers (DPIs), and nebulizers.
The primary objective of ICSs therapy in patients
with asthma or COPD is to deliver sufficiently high
concentrations of the drug to the bronchial
mucosa, while minimizing the amount of drug
reaching the systemic circulation and thus reducing
the potential for adverse systemic and local side
effects. Many factors influence the distribution of
an aerosolized drug throughout the tracheobron-
chial tract and its subsequent metabolic fate and
therapeutic effects. These factors can be divided
into three major categories (Table 1): drug- and formulation-related factors;
 device-related variables;
 patient- and disease-related factors.Table 1 Factors affecting the clinical outcome of thera
Drug- and formulation-related
factors
Device-related fact
Potency and airway selectivity of
the drug
Lung deposition pro
Pharmacokinetic profile of the drug Aerosol particle siz
Pulmonary and oral
bioavailability
Ease of use
Local retention Dosage accuracy
Particle size Extrathoracic depo
for local and system
Choice of propellant (pMDIs) Driving gas flow (ne
Irritancy of additives Choice of face mask
(nebulizers)
Viscosity and surface tension of
nebulization solution
Abbreviation: pMDIs, pressurized metered-dose inhalers.to address the different clinical circumstances and
A range of delivery devices have been developed
patient types receiving ICSs treatment. The clinical
benefit of therapy is affected by the nature and
extent of the patient’s disease, the drug and
formulation, the characteristics of the device,
and the patient’s ability to use the device correctly.
An understanding of these factors is necessary
when considering the most appropriate treatment
option. The aim of this review is to examine the
key factors influencing the relative clinical efficacy
and safety of the different inhalation systems for
the delivery of corticosteroids to patients with
asthma and COPD, and thus help guide selection of
the most appropriate delivery device for the
individual patient.
Throughout this review, the corticosteroid, bu-
desonide, has been used as an example to explain
the impact of these factors using various delivery
devices. Budesonide has been selected for this role
in view of the extensive evidence demonstrating its
efficacy in the treatment of persistent asthma
across all age groups.5Delivery options for inhaled
corticosteroids
pMDIs consist of a pressurized aerosol canister that
contains the medication either dissolved or sus-
pended in liquefied gas propellant(s), together with
surfactants and other excipients, such as preserva-
tives and flavourings. A metering system controls
the volume of drug mixture that is released whenpy with an ICS.
ors Patient- and disease-related
factors
perties Inspiratory flow rate
e Upper airway anatomy
Lower airway obstruction
Ability to use device effectively
(competence)
sition (relevant
ic side effects)
Patient preference
bulizers) Patient adherence
or mouthpiece Handling and maintenance of the
device
Breathing pattern (nebulizers)
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L. Thorsson, D. Geller838the actuator is pressed. The propellant that forms
the aerosol has historically been a chlorofluorocar-
bon (CFC), but due to environmental concerns,
they are gradually being replaced with hydrofluor-
oalkanes (HFAs). Most HFA formulations have a
gentler plume (slower particle velocity) and the
solution HFA formulations have reduced particle
size that can dramatically influence lung deposition
vs. a CFC suspension.6 About 80–90% of the ICSs
dose from a CFC-pMDI is deposited in the orophar-
ynx where it can cause local side effects. Further-
more, a major limitation of pMDIs is that they
require coordination of actuation and inhalation.
Effective patient instruction, including practice
with a placebo device, is therefore essential.
Patients may also have difficulty using the mouth-
piece of the actuator, and the cold temperature of
the aerosol when it hits the back of the throat may
cause the user to interrupt inhalation (known as the
’ ’
cold Freons effect’’).
A host of add-on devices for pMDIs have been
designed to overcome these limitations. Spacers
and valved holding chambers are designed to reduce
high oropharyngeal drug deposition and eliminate
the cold Freons effect. Valved holding chambers
can also reduce drug loss caused by poor hand–
breath coordination. Breath-actuated or flow-trig-
gered pMDIs were developed to overcome the need
for hand–breath coordination. However, these
devices still require a proper technique when used
with a slow inhalation and a breath-hold, which may
be difficult for some patients, particularly young
children. Therefore, valved holding chambers with
face masks are available for infants and young
children and are used with tidal breathing.
DPIs offer an alternative response to the diffi-
culties associated with pMDIs, and are actuated and
driven by inspiratory flow. These devices create the
aerosol by passing air from the inspiratory effort
through medication formulated as a dry powder.
The active ingredient is in the form of micronized
drug particles that can be mixed with larger
glucose or lactose particles, or bound into loose
aggregates. Micronized particles tend to adhere
strongly to each other and to most surfaces, and
disaggregation must occur for the drug to be
delivered effectively. Disaggregation occurs during
inhalation when the powder is broken up into its
constituent particles by turbulent airflow and/or
mechanical devices, such as screens or spinning
surfaces. One type of DPI is TurbuhalerTM, which is
routinely used for the delivery of asthma medica-
tion. TurbuhalerTM has a built-in resistance in the
form of a spiral-shaped air passage that promotes
the separation of the dry-powder microaggregates
of drug into particles of respirable size before theyleave the inhaler. However, with this formulation it
is important to educate the patient that the aerosol
has no flavour, otherwise the patient may be unsure
whether a dose was delivered by the device.
Nebulizers have been available in one form or
another for over a century. They produce a fine mist
of droplets that contains the active drug. Nebuli-
zers are a practical means of administering inhaled
medications to very young children and patients
who are unable to use other inhaler devices. They
are also used in preventive and emergency con-
texts. There are two classic types of nebulizers,
which are classified according to how they produce
the droplets. Jet nebulizers use a source of
compressed air forced through a small orifice,
forming an air jet that transforms a liquid into
primary aerosol droplets. The larger particles
impact on internal baffles and are recirculated,
while the smaller particles exit the nebulizer and
are available for inhalation. Ultrasonic nebulizers
produce the droplets by mechanical vibration of a
piezoelectric plate, creating a geyser or fountain
effect from which particles of the liquid are
created. The former type is less complex, cheaper
and therefore more commonly used. The drug is
contained in an aqueous solution or as a suspension
(Pulmicort Respuless [budesonide]) in which small
particles are suspended in the fluid. The mist is
then inhaled via a mouthpiece or a face mask. New
types of nebulizers, such as those that use vibrating
porous membrane technology, are under develop-
ment and may be useful for both solutions and
certain suspensions.Preclinical and clinical pharmacologic
comparison of the delivery options for
inhaled budesonide
In vitro characteristics of the device
Aerosol particle/droplet size is one of the most
important factors determining the deposition of
ICSs in the airways.7,8 The portion of an aerosol
that has the highest probability of bypassing the
upper airway and depositing in the lung measure
between 1 and 5 mm.9 Particles larger than this are
generally deposit in the oropharyngeal region and
are swallowed, while submicronic particles do not
carry much drug and may be exhaled before
deposition takes place. Smaller particles tend to
deposit more peripherally in the lung than coarser
particles, which may lead to a different clinical
response.10 Consequently, differences in particle
size of the aerosol emitted from inhalation devices
ARTICLE IN PRESS
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Budesonide
Turbuhaler® 
(40, 60, 80 l/min)
Beclomethasone
Chiesi inhaler
(19, 29, 38 l/min)
Beclomethasone
Diskhaler® 
(79, 118, 158 l/min)
Inhaled corticosteroids in the asthma and COPD 839may account for some of the variability in
therapeutic efficacy and safety of the various ICSs.
Measurement of particle size, therefore, has an
important role in guiding product development and
in quality control of the marketed product.
The distribution of aerosol particle/droplet size
can be expressed in terms of either:60al 
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50the mass median aerodynamic diameter
(MMAD)—the droplet size at which half of the
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Figure 1 The proportion of the nominal dose of
budesonide, beclomethasone dipropionate, or flutica-
sone delivered as fine particles (diameter o5mm) from
four different DPIs at flow rates corresponding to weak,
moderate, and strong inspiratory forces in an in vitro
model.11the fine particle fraction—the percentage of
particles that are o5 mm in diameter.
These measures have been used for comparisons
of the in vitro performance of different inhaler
device and drug combinations. In general, the
higher the fine particle fraction, the higher the
proportion of the emitted dose that is likely to
reach the lung. Fine particle fraction (and conse-
quently fine particle dose) can be assessed by
drawing aerosols through an Andersen multi-stage
sampler (an impactor device fitted with a series of
filters that collect progressively smaller particles).
The inhaler and impactor are connected via an inlet
throat. These laboratory assessments of fine parti-
cle dose have been shown to correlate well with
lung deposition in humans if the traditional inlet
throat is replaced with an anatomically accurate
replica or cast of the human throat.7 Interestingly,
the choice of inlet throat has a significant effect on
the fine particle dose recovered from a pMDI (50%
difference in fine particle fraction between throats)
but considerably less influence on that recovered
from a DPI (15% difference).11 This suggests that in
humans, the interaction between the throat and the
aerosol cloud is greater for an aerosol generated by
a pMDI than for one generated via a DPI.7
Using the anatomically correct throat method
described above, Olsson11 has shown that the in
vitro fine particle dose of budesonide (expressed as
a per cent of the nominal dose) via TurbuhalerTM
DPI is approximately twice that achieved via a
pMDI. Conversely, for fluticasone propionate (here-
after referred to as fluticasone) the opposite
appears to be true—i.e. the fine particle dose
delivered via pMDI is about twice that via the
Diskhalers DPI.11 This illustrates the point that all
inhaled formulations have unique properties;
hence, no general conclusions should be made for
DPIs, pMDIs, or nebulizers. Figure 1 shows an in
vitro comparison (using similar methodology to that
described above) of the proportion of the nominal
dose of budesonide, beclomethasone dipropionate,
or fluticasone delivered as fine drug particles(o5 mm) from four different DPIs at flow rates
corresponding to weak, moderate, and strong
inspiratory force.11 Comparable degrees of inspira-
tory force, rather than identical flow rates, were
used since different DPIs offer different resistance
to inspiratory flow. These data show that the
budesonide TurbuhalerTM device consistently pro-
duced a higher proportion of respirable particles
than the other devices (even when the inspiratory
force was relatively weak), indicating that this
device could be considered for patients with
relatively low inspiratory abilities.Pulmonary/extrapulmonary deposition and
inhalation characteristics
The clinical efficacy and safety of ICSs in asthma
and COPD is dependent upon maximizing the
proportion of the dose that is delivered to the
lungs and airways, while minimizing systemic
exposure to the drug. While in vitro assessments
of fine particle mass do provide some predictive
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within the tracheobronchial tree, a number of
other factors (plume geometry [pMDIs], particle
inertia, breathing pattern, inhalation flow, and
disease-related changes in airway geometry and
flow) also influence pulmonary disposition. There-
fore, in vivo deposition studies are also needed to
support the in vitro findings.8
There are two main methods used to measure
aerosol deposition in the lungs. First, g-scintigraphy
is performed by radiolabelling the drug with a
substance like 99m-technetium, and scanning the
subject after inhalation of the drug. This technique
has the advantage of being able to quantify the
proportion of aerosol inhaled by the patient, as
well as regional distribution in the upper airway
and lungs. Second, since most of the ICSs deposited
in the lower airways will be absorbed into the
bloodstream, pharmacokinetic techniques are used
to measure lung deposition. This technique can
assess the total amount of ICSs that interacts with
the airway epithelium and is absorbed systemically,
but will miss the small portion that may be
expectorated or swallowed after mucociliary clear-
ance, and cannot tell us about regional distribu-
tion. Therefore, g-scintigraphy and pharmaco-
kinetic studies are complementary, and have bothTable 2 Fine particle mass (presented as percentage of
available devices for delivery of ICSs (deposition data for
Reference Device Lung de
Per cent
nominal
Budesonide
Dahlstro¨m et al.13 PARI Inhalierboys 14
PARI LC Jet Pluss 14
Maxin MA-2s 14
Borgstro¨m12 and
Thorsson et al.14
pMDI (no spacer) 15
Thorsson and
Edsba¨cker15
pMDI plus spacer 36
34
Borgstro¨m,12 Thorsson
et al.,14,16 Borgstro¨m
et al.,17 and Agertoft
and Pedersen18
TurbuhalerTM 28–32
Fluticasone propionate
Thorsson et al.16 PMDI 20
Thorsson et al.16 and
Agertoft and
Pedersen18
Diskuss 8–12
Abbreviation: pMDI, pressurized metered-dose inhaler.been used for budesonide and other ICSs delivered
by nebulizers, MDIs and DPIs.
Deposition studies have shown significant differ-
ences between devices with respect to pulmonary
deposition of corticosteroids, with values ranging
from approximately 5% to over 50% (ex-actuator
or delivered dose, respectively) for currently
available corticosteroid pMDIs and DPI systems
(Table 2).6,12 For example, Thorsson et al.14
reported that lung deposition of budesonide in
healthy volunteers was approximately twice as high
when the drug was delivered via TurbuhalerTM than
via a pMDI (32% and 15% of the metered dose,
respectively). Moreover, TurbuhalerTM deposited
less drug in the mouth than pMDI, resulting in a
more beneficial ratio of pulmonary to total
systemic bioavailability (Fig. 2). In this study,
deposition was calculated by two methods: from
systemic availability (corrected for an assumed oral
bioavailability of 13%) and using the charcoal block
technique (in which activated charcoal suspension
is used to adsorb swallowed drug, preventing its
systemic absorption); similar results were obtained
with each of the techniques (Table 2). The doubling
in pulmonary deposition of budesonide with Turbu-
halerTM compared with pMDI14 is consistent with in
vitro fine particle results obtained using an Ander-dose) and estimated lung deposition of the currently
healthy volunteers).
position Systemic availability
(per cent of nominal
dose)
of
dose
Per cent of dose
to subject
36 17
58 15
59 17
21–26
36
35
59 33–38
31 21
17 13
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Figure 3 Lung deposition of radiolabelled budesonide,
measured by g-scintigraphy, following administration of
budesonide via (a) pMDI, (b) pMDI plus Nebuhaler, and (c)
TurbuhalerTM.19
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Figure 2 Systemic availability of budesonide following
single-dose administration via TurbuhalerTM and pMDI to
healthy volunteers, expressed as (a) per cent of the
nominal dose and (b) per cent of the lung dose.14
Inhaled corticosteroids in the asthma and COPD 841sen sampler fitted with an anatomical throat
model.11 This finding suggests that in the case of
budesonide, this in vitro technique may be a useful
predictor of relative lung deposition.
There are significant differences between the
deposition characteristics of various DPIs as well.
For example, Thorsson et al.16 evaluated the
pharmacokinetics of budesonide delivered by Tur-
buhaler vs. fluticasone delivered by a pMDI and by
Diskus DPI in 13 healthy adult volunteers and eight
adults with asthma. The delivery to the lung with
the Turbuhaler was almost twice that of the pMDI
and almost three times that of the Diskus (34%,
20%, and 13%, respectively). Similarly, in a group of
children ages 8–14 years, the lung dose of
budesonide via Turbuhaler was almost four times
that of the fluticasone Diskus (30.8% vs. 8.00%).18
One cannot comment on the superiority of a drug-
device combination based on lung deposition alone,
but the effectiveness of topical therapy obviously
depends on the medication being delivered to the
airways target effectively.
The efficiency of a pMDI at delivering drug to the
lung can be improved by using the pMDI in
conjunction with a large-volume spacer or valved
holding chamber. In healthy volunteers, lung
deposition of budesonide from a pMDI plus Neb-
uhalers (not available in the US) was estimated
using pharmacokinetic methods to be 36% of the
metered dose.15 Similarly, in patients with asthma,
the mean lung deposition, measured by g-scinti-
graphy, was 38% from pMDI plus Nebuhalers
compared with 26% from TurbuhalerTM, and 12%
from a pMDI alone (Fig. 3).19 Another study showed
that the efficacy of a pMDI plus Nebuhalers used
under ideal circumstances could indeed match theclinical efficacy of budesonide TurbuhalerTM.20
However, the high lung deposition of budesonide
reported in these studies with a pMDI plus
Nebuhalers does not appear to translate into
superior clinical efficacy compared with Turbuha-
lerTM in routine practice (as explained in the
subsequent sections).21 This may be related to
problems in using pMDIs plus spacers correctly or to
poor adherence in routine clinical practice, as
opposed to the highly controlled environment in
which clinical trials are performed.15,22 Alterna-
tively, subjects may have already been on the
plateau of the dose–response curve, so using a
more efficient device may not have improved
clinical outcome.
While some of the newer HFA-propellant pMDIs
are formulated with the drug in suspension, most
have the drug in solution, e.g. beclomethasone
propionate, flunisolide, and ciclesonide. Beclo-
methasone has an MMAD close to 1 mm and an ex-
actuator deposition efficiency of about 50% in
adults6 and greater than 30% in children.23 The
fluticasone HFA formulation has a larger particle
size to emulate the CFC preparation.
In children or adults who are unable to use a pMDI
or DPI correctly, a jet nebulizer can be used to
deliver therapeutic levels of any corticosteroid
available as a nebulizing suspension (beclometha-
sone and budesonide) to the lungs. Dahlstro¨m
et al.13 assessed lung deposition of budesonide by
pharmacokinetic methods in adult volunteers from
three different jet nebulizer systems—the PARI
Inhalierboys, PARI LC Jet Pluss, and Maxin MA-2s.
The MMAD for the Inhalierboys, Jet Pluss, and MA-
2s systems were 7, 5, and 3 mm, respectively.
Relative to the nominal budesonide dose, lung
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tested, ranging from 14% to 16%, despite the
differences in particle size distributions. This
emphasizes the fact that particle size is only one
of the important variables in the assessment of
aerosol delivery system performance. In this study,
even though the PARI Inhalierboys produced larger
particles that are less likely to deposit in the lungs,
it had a higher total output of drug than the other
nebulizers which compensated for the particle size
problem. The pharmacokinetics of budesonide
nebulizing suspension have also been studied in
asthmatic preschool children aged 3–6 years, using
a PARI LC PLUS with a mouthpiece. Lung deposition
as a per cent of inhaled dose was 18%, and the
systemic bioavailability was 6%, which is about half
that of adults.24 This indicates that the lower total
lung dose in children is due to the increased
fraction of the drug filtered out by the oropharynx
(which does not add significantly to the systemic
load) indicating the same doses can safely be used
in children as adults.
Ultrasonic nebulizers are not well suited for
suspensions, as demonstrated in several stu-
dies.25–27 For example, in one study the median
inhaled mass of budesonide was approximately
three-fold lower with an ultrasonic nebulizer
compared with a jet nebulizer (10% of the nominal
dose vs. 31%).28 For this reason, ultrasonic nebuli-
zers are not recommended for use with budesonide
nebulizing suspension.
Lung deposition and inhaled mass of nebulizer
corticosteroids are also significantly influenced by
the choice of patient–device interface, with use of
a mouthpiece being shown to double lung deposi-
tion compared with use of a face mask.29 For
example, one study of 158 children with asthma
(ages 5–15 years) reported a mean inhaled mass of
5–7% of the nominal dose when budesonide was
administered at a constant output using a jet
nebulizer fitted with a unsealed face mask,
compared with 9–12% when the same device was
used at the same output but using a mouthpiece.29
Based on these data, the authors recommended
that the use of non-sealing face masks with jet
nebulizers should be avoided where possible. Mean
inhaled mass could be further increased by switch-
ing the jet nebulizer from constant output to the
breath-synchronized mode (an increase of up to
17–22% when used in conjunction with a mouth-
piece).29 Despite the higher inhaled mass noted
with the mouthpiece vs. the mask, a large clinical
trial showed improvement in asthma symptom
scores of similar magnitude between the two
patient–device interfaces.30 In this study of infants
and children aged 6 months to 8 years, the maskwas used more in the younger children (mean 36.4
months) and the mouthpiece in older children
(mean 70.0 months). The similar clinical effect
between groups may be due to the smaller lungs
and therefore a lower lung-dose requirement in the
younger children.
Relationship between pulmonary deposition and
therapeutic effect
The relationship between pulmonary deposition of
inhaled b2-agonists and therapeutic effect is now
well established8,31,32 since the immediate effects
of these agents on the airways are relatively easy to
measure.8 As the pulmonary dose–response curve
for the b2-agonists is sigmoidal (i.e. an initial slope
followed by a plateau), increasing the dose
deposited in the lung will elicit an increased
therapeutic effect only if the initial dose was on
the rising slope of the dose–response curve. The
lack of measurable acute effects with ICSs makes it
impossible to perform similar single-dose studies
with these agents, although there are now a
number of long-term studies suggesting that the
relationship also holds true for corticoster-
oids.8,33,34 Therefore, for patients whose symptoms
are not currently under control, switching from an
ICSs device with a low pulmonary deposition to one
with a high pulmonary deposition may prove
advantageous. Conversely, for patients whose dis-
ease is well managed and who are using an ICSs
device with a high pulmonary deposition, every
effort should be made to reduce the dose to avoid
unnecessary systemic side effects. The relationship
between the site of drug deposition in the lung and
therapeutic effect is, however, less well under-
stood.8
Consistency of lung deposition
Dose reproducibility is an important consideration
for ICSs therapy. In vitro assessments of device
consistency appear to be poor predictors of lung-
deposition consistency in vivo. For example, the
fluticasone Diskuss inhaler has shown less varia-
bility in distribution of aerosol particle sizes than
budesonide TurbuhalerTM in in vitro simulations
and, based on this, it has been argued that greater
consistency in lung deposition could be expected
with the Diskuss device.35,36 However, this has not
been borne out in vivo; conversely, TurbuhalerTM
has shown less variability in lung deposition than
the Diskuss inhaler in children and adults.18,37
TurbuhalerTM was also found to provide greater
consistency in terms of budesonide lung-deposition
in vivo when compared with a pMDI, in spite of the
fact that in vitro the variability in drug delivery was
markedly less for the pMDI.14 This discrepancy
ARTICLE IN PRESS
Inhaled corticosteroids in the asthma and COPD 843between in vitro and in vivo consistency may be
due, in part, to a difference in aerosol particle size
distributions between inhalers. Compared with the
Diskuss inhaler, TurbuhalerTM delivers 3–4 times as
many fine particles, which may deposit more
consistently and/or more peripherally in the
intrapulmonary airways than larger particles. The
difference between in vitro and in vivo results
may, however, simply reflect the fact that the
relatively small variability seen under standardized
in vitro conditions becomes insignificant when
biological and clinical factors (e.g. inhalation
technique, airway geometry, and flow) are also
considered.18,31
Lung deposition: misconceptions about
effectiveness of devices
Dose delivery from DPIs such as TurbuhalerTM is
reliant upon patients being able to generate an
adequate peak inspiratory flow to disaggregate the
drug into particles small enough to reach the lungs.
For such devices, patients with large lung volumes
generating high inspiratory flows are likely to attain
high levels of drug deposition in the lungs. Some
patients groups—notably asthmatic children and
patients with advanced COPD—are often perceived
as being unable to generate a sufficient inspiratory
flow to achieve adequate clinical benefit from
inhalation of medication via a DPI. However, a
recent review of the literature7 has shown this to
be a misconception.
Contrary to popular belief, patients with acute
asthma are able to generate a high inspiratory flow
through a DPI. The duration of the inspiratory flow,
however, is shorter in this scenario due to a lower
inspiratory volume. In this situation, a DPI is
actually likely to perform better than a pMDI,
particularly given the problems of coordinating
actuation and inhalation during an acute asthma
exacerbation.7 In one study of 99 adults presenting
to hospital with acute exacerbations of asthma,
98% generated an inspiratory flow through Turbu-
halerTM greater than 30 l/min, which is ideal for
achieving an optimal clinical effect (only two
patients recorded 26 l/min), the mean peak in-
spiratory flow being 60 l/min.38 Comparable find-
ings have also been reported in studies in children
with asthma39 and in patients with COPD.40 Indeed,
in a study of 82 children with mild–moderate
asthma, all children were capable of inhaling
through a TurbuhalerTM at a flow rate 440 l/min
(mean values of 59 and 70 l/min for children aged
3–6 and 7–10 years, respectively).39 In children,
there appears to be significant correlation between
lung deposition of budesonide (delivered via Tur-
buhalerTM, NebuChambers or nebulizer) and thesize (diameter) of the mouth and oropharynx,41–43
while systemic exposure to the drug (i.e. lung
deposition) was similar in small children and
adults.42 This implies that from a safety perspec-
tive, the same doses can be used in children and
adults without increasing the risk of systemic
exposure. Importantly, the lower absolute lung
deposition in children is offset by a higher orally
deposited fraction, which does not contribute
significantly to the total systemic load.Clinical efficacy and safety of
budesonide: influence of device
Clinical efficacy
Given the differences in inhalation characteristics
and pulmonary deposition, it is not surprising that
the various corticosteroid delivery systems also
appear to have very different efficacy and safety
profiles when administered to patients with asthma
or COPD. The extensive clinical trial programme for
budesonide has included all three major device
types, and has demonstrated good efficacy for
budesonide in the management of persistent
asthma (irrespective of disease severity) in patients
of all ages, as well as in the acute asthma setting
and in patients with COPD.5
pMDIs are the most established means for ICSs
delivery and have therefore been the benchmark
against which new corticosteroid inhalation devices
have been judged and against which dose selections
for the new systems have been made. In the case of
budesonide, results from early clinical studies
comparing the efficacy of the same nominal dose
of budesonide given via pMDI or via the Turbuha-
lerTM DPI showed a clear improvement in peak
expiratory flow with the TurbuhalerTM compared
with a pMDI.44–46 Subsequent randomized trials
have calculated the difference in the dose:potency
ratio of clinical efficacy between the two modes of
administration to be approximately 2:1, indicating
that when using TurbuhalerTM only half the nominal
dose of budesonide needs to be given to achieve
the same clinical efficacy as the full dose given via
pMDI.21,47–49 For example, Agertoft and Pedersen21
compared the efficacy and safety of a pMDI and
spacer device (Nebuhalers) with TurbuhalerTM for
the delivery of budesonide to children with chronic
perennial asthma who were previously treated with
budesonide via pMDI. Initially, 241 children with
asthma had their dose of budesonide optimized
during a run-in period. Once their asthma had
stabilized, these children were then randomized to
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pMDI plus spacer or half the original dose delivered
via TurbuhalerTM. Compared with the pMDI plus
spacer, TurbuhalerTM was found to be at least as
effective in terms of peak expiratory flow measure-
ments and was also associated with a reduction in
b2-agonist use.
Agertoft and Pedersen33 also compared the
efficacy of budesonide TurbuhalerTM and pMDI plus
Nebuhalers in 216 children aged 6–14 years with
chronic asthma who had received budesonide for
3–6 years. In this study, the budesonide dose was
titrated down until optimal asthma control was
reached. Although the mean dose of budesonide
over the study period was significantly lower with
TurbuhalerTM than with pMDI plus Nebuhalers
(447 mg vs. 612 mg), children treated with Turbuha-
lerTM experienced significantly greater improve-
ments in pulmonary function compared with those
using the pMDI plus spacer (Fig. 4).
A 2:1 clinical potency ratio has also been
demonstrated for budesonide via TurbuhalerTM
relative to budesonide via pMDI without spacer in
adults with asthma.47 In a general practice, study
of 631 adults whose asthma was adequately
controlled with inhaled budesonide or beclometha-
sone (200 or 400–500 mg twice daily, respectively)
administered via pMDI, switching to half the daily
dose of budesonide via TurbuhalerTM either once
daily or in two divided doses was not associated
with any loss in asthma control. Importantly, no
significant differences were noted in peak expira-
tory flow, asthma symptom scores, bronchodilator
use, or quality of life measures between those
remaining on their usual treatment via pMDI0
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Figure 4 Mean daily dose of budesonide required for
optimal asthma control and pulmonary function in
children with asthma receiving budesonide via Turbuha-
lerTM or via a pMDI plus Nebuhalers for 3–6 years.23and those switching to half-dose budesonide
via TurbuhalerTM. Based on these findings,
attempts should be made to reduce the dose of
budesonide when patients are switched from
budesonide pMDIs to TurbuhalerTM treatment. The
2:1 clinical potency ratio for TurbuhalerTM relative
to pMDI is consistent with the finding that budeso-
nide lung deposition achieved with TurbuhalerTM is
approximately twice that achieved with pMDI.14
Increased adherence and ease of use for Turbuha-
lerTM relative to pMDI might also contribute to
these findings.50
Nebulization provides a useful alternative mode
of delivery of corticosteroids that are available as a
nebulizing suspension (beclomethasone and bude-
sonide) in situations where a DPI or pMDI may not
be suitable. Situations where budesonide inhalation
suspension (Pulmicort Respuless) would prove
useful include: Children up to 5 years of age (approved up to 8
years of age in the US). Patients 45 years of age who experience
difficulty using pMDIs or DPIs. Patients of any age who cannot coordinate or
activate a pMDI or DPI because of dyspnoea.In the case of budesonide, the clinical trial
programme of the inhalation suspension has
included infants and children up to 8 years of
age with asthma severity ranging from mild to
moderate. In this population, nebulized budesonide
proved effective at daily doses of between 0.25
and 1mg (administered as a single daily dose or
in two divided doses) (Fig. 5)51,52 and has
been found to be equally effective both in children
o4 and X4 years of age.53 Shapiro et al.54 studied
children ages 4–8 years with more severe asthma,
who were already receiving ICSs at baseline.
Doses up to 1mg twice daily were effective
at improving morning peak flow and reducing
symptoms and need for rescue medication.54
Budesonide delivered via nebulization has been
shown to be significantly more effective
than placebo and sodium cromoglycate at improv-
ing symptoms and reducing asthma exacerbations
in children with persistent asthma.55 In adults,
high-dose budesonide (within the recommended
dose range) via nebulization (synchronized with
inhalation to minimize loss of drug) is more
effective than budesonide delivered via pMDI
plus spacer in managing severe persistent asthma,
thus reducing the requirement for oral steroids
and improving asthma symptoms and lung function
(Fig. 6).35
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Figure 5 Mean improvement in nighttime and daytime asthma symptom scores in infants and young children treated
with nebulized budesonide (Pulmicort Respuless) 0.25, 0.5, or 1mg once daily, or placebo for 12 weeks.52
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Figure 6 Morning and evening peak expiratory flow
during twice-daily treatment with budesonide nebulizing
solution (Pulmicort Respuless) 1 or 4mg, or budesonide
800 mg via pMDI with Nebuhalers, in patients with
moderate or severe unstable asthma.35
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Choice of inhalation device also has a significant
impact on the nature and extent of side effectsexperienced with ICSs. Although systemic toxicities
can occur at high doses of ICSs, in routine clinical
practice it is the local side effects of these
drugs—particularly hoarseness and oral candidia-
sis—that are the most frequent. Local side effects
can be reduced by mouth rinsing after inhalation.
Also, use of a valved holding chamber in conjunction
with a pMDI reduces oropharyngeal deposition from
approximately 80% of the metered dose to 10–15%.56
Since DPIs are used without spacers, there have been
concerns that use of these devices may lead to
increased local side effects. However, data from
clinical studies with budesonide suggest the opposite
to be the case. Selroos et al.49 monitored the
incidence of local adverse events in 154 patients
treated with budesonide or beclomethasone via a
pMDI plus large-volume spacer (Nebuhalers or
Volumatics, respectively) for 2 years, after which
they were switched to budesonide TurbuhalerTM and
followed for a further 2 years. The incidence of local
adverse events (candidiasis, hoarseness, or sore
throat or gums) in patients receiving budesonide or
beclomethasone via pMDI plus spacer was 17% and
23%, respectively, decreasing to 6% (Po0:001 vs.
pMDI) when the patients were switched to budeso-
nide TurbuhalerTM. This large decrease was due
mainly to a reduction in the incidence of hoarseness,
which may be related to irritating additives and
propellants used in the pMDI.
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The systemic safety profile is an important con-
sideration of any treatment used long term in the
control of a chronic disease. If administered at high
enough doses, all ICSs will produce clinically
significant systemic activity. The systemic side
effects of the available ICSs when used within the
recommended dose ranges have been compared
previously.57–60 Budesonide is the most thoroughly
investigated ICSs in terms of long-term tolerabil-
ity.3,61–65 Specifically, long-term use of budesonide
is reported to have no adverse effect on final adult
height of paediatric patients, bone mineral density,
or ocular changes,3,62–65 and is the only ICSs
assigned a Pregnancy Category B rating by the US
Food and Drug Administration; all other ICSs remain
at a Pregnancy Category C rating.Competence, adherence, and continuity
The therapeutic effectiveness of any ICSs delivery
device ultimately rests with the patient or care-
giver, and in their ability to use the device correctly
(competence) and as instructed by their physician
(adherence). Indeed, it has been suggested that
adherence is the major factor determining asthma
control during long-term treatment.66
Poor inhaler technique is a major problem for
ICSs therapy, particularly for pMDIs that require
coordination between actuation and inhalation.
The cold Freons effect may also interrupt inhala-
tion. Indeed, it has been estimated that as many as
two-thirds of pMDI users and healthcare profes-
sionals teaching pMDI use do not perform the
technique correctly.67,68 While poor technique
results in inadequate doses of medication being
administered, this can be substantially improved by
good patient education. However, even following
proper instruction, patients of all ages may be
unable to use pMDIs efficiently.69,70 Use of a spacer
or a valved holding chamber in conjunction with a
pMDI can help coordinate actuation with inhalation
and substantially reduce oropharyngeal deposition
and the cold Freons effect.
For patients experiencing problems using a pMDI,
a DPI such as TurbuhalerTM might be a practical
alternative. The generation of the aerosol from
Turbuhaler is breath-initiated (eliminating the
problem of coordinating inspiration with actua-
tion), and the particle speed is equal to the velocity
of the inspired air. This functional difference may
explain why lung deposition is less variable when
the drug is delivered via TurbuhalerTM compared
with delivery via a pMDI.71There are special considerations for optimizing
aerosol delivery for infants and toddlers. Many
young children fuss or cry when a mask from a
nebulizer or holding chamber is applied to the face.
However, crying significantly reduces the amount of
aerosolized drug that reaches the lungs72–74 and
increases dose-to-dose variability.75 To avoid cry-
ing, some caregivers will move the mask away from
the face and give
’ ’
blow-by’’ treatments. However,
a poor face mask seal will result in 40–85% declines
in inhaled dose with both MDI/spacer devices 76,77
and nebulizers.78,79 Techniques that may overcome
these problems include administering the aerosol
during sleep,80 using an aerosol hood,81 or using
blow-by with a tube or mouthpiece (rather than a
mask) held within 4 cm of the child’s nose.82
Though no significant ocular problems have been
reported in children taking usual doses of ICSs, care
should be given to avoid direct drug exposure to the
eyes of the child. New face masks are being
designed to reduce eye exposure.83
When selecting the optimal device for delivery of
ICSs to an individual, patient preference should be
a key consideration since it is one of the determi-
nants of patient adherence to medication. Many
causes of non-adherence with inhaled medication
have been identified. Those relating to the device
itself include low portability, impracticality, and
difficulties in use. Also, reimbursement issues for
durable medical equipment (spacers, nebulizers,
and compressors) may play a significant role in the
choice for many patients.
Budesonide is currently the only ICSs available
for delivery via all three major types of devices
for which in vivo lung deposition, pharmacokinetics
and clinical efficacy have been investigated.
This range of inhalation systems allows budeso-
nide to be delivered effectively to patients of
all ages and asthma severities. It allows the
clinician and the patient to decide as a team
which delivery system is best for them. Indeed,
children with asthma may continue with the
same drug as they mature; e.g. infants can be
treated with Pulmicort Respuless and later
switched to budesonide TurbuhalerTM at 5–6 years
of age, if given appropriate training.62 This con-
tinuity of drug therapy throughout childhood and
into adulthood helps the caregiver develop con-
fidence in the drug.Conclusions
ICSs are the cornerstone of therapy for patients
with asthma and reduce exacerbations in patients
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addition to improving lung function and asthma
symptoms, ICSs significantly reduce the incidence
of mortality and exacerbations requiring emer-
gency physician visits, oral corticosteroid bursts,
and hospitalizations. Indeed, ICSs therapy is now
recommended as first-line therapy for all patients
with persistent asthma. A range of delivery devices
have been developed to cope with the different
clinical circumstances and patient types receiving
ICSs treatment. The clinical benefit of such therapy
is determined by a complex interplay between the
nature and extent of disease, the drug and its
formulation, the characteristics of the device, and
the patient’s ability to use the device correctly.
An understanding of these factors is necessary
when considering the most appropriate treatment
option.
The corticosteroid, budesonide, is available for
delivery via each of the three major types of
inhalation devices, allowing physicians to select the
optimal device for a particular patient, in addition
to offering continuity in drug therapy as the child
grows. When delivered by any of these devices,
budesonide has been found to be effective in the
treatment of persistent asthma irrespective of
severity and age. Efficacy has also been demon-
strated in patients with acute asthma and those
with COPD. The ability to choose the appropriate
aerosol delivery system for budesonide that
matches the individual needs of the patient will
help achieve successful treatment of obstructive
airway diseases.References
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